Episode Summary
Executive Summary: Peter Attia and Dr. Ethan Weiss discuss why The Drive avoids ads, then dive into a wide-ranging masterclass on coronary disease, stents, and modern cardiac diagnostics. They also explore Weiss’s lab work on growth hormone/IGF-1, sex differences, fasting, insulin sensitivity, and his new acetone breath analyzer startup, Keyto.
Main Topics: Podcast funding, trust, and listener support (Priority: 5/5): Attia explains why the show rejects advertising in favor of subscriptions, arguing that ad-free funding preserves trust, honesty, and editorial independence while still supporting high-quality show notes and member benefits. Evolution of coronary disease and MI nomenclature (Priority: 5/5): Weiss traces the shift from older concepts like Q-wave vs non-Q-wave MI and unstable angina to modern STEMI/NSTEMI/ACS terminology, emphasizing plaque rupture, thrombosis, and the importance of ECG interpretation. Stents, angioplasty, and when intervention helps (Priority: 5/5): The discussion reviews balloon angioplasty, bare-metal stents, drug-eluting stents, restenosis, stent thrombosis, and dual antiplatelet therapy, highlighting that stents clearly save lives in STEMI but are mainly symptom-relief tools in stable angina. Trials shaping stable angina care (Priority: 5/5): Courage and Orbita are used to show that in stable coronary disease, routine stenting does not improve hard outcomes and may not even outperform optimized medical therapy for symptoms in many patients. Calcium scoring, CTA, and HeartFlow (Priority: 4/5): They compare coronary calcium scoring, CT angiography, and CT-derived FFR/HeartFlow, focusing on how these tests inform risk and treatment intensity rather than serving as universal screening tools. Growth hormone, IGF-1, and metabolic biology (Priority: 5/5): Weiss explains his lab’s work showing that growth hormone signaling in liver and adipose tissue affects IGF-1, fatty liver, insulin sensitivity, and broader metabolic regulation, with implications for aging and disease. Keyto breath acetone device and behavior change (Priority: 3/5): The conversation closes with Weiss describing Keyto, a breath acetone analyzer designed to give real-time feedback for ketogenic dieting and fasting, aiming to improve adherence and behavior change.
Key Arguments: Ad-free podcasting preserves trust because listeners are not hearing paid endorsements from companies that sponsor the host. In acute coronary syndromes, the key pathophysiology is plaque rupture with thrombosis, not simply progressive narrowing of the artery. STEMI is a true emergency where immediate cath lab activation and reperfusion save myocardium and lives. Stable angina is usually a symptom-management problem; stents often improve symptoms but generally have not shown mortality benefit in this setting. Courage and Orbita collectively weakened the case for routine stenting in stable coronary disease, reinforcing optimized medical therapy first. Coronary calcium scoring is most useful at the extremes of age and risk; a zero score in an older person is more informative than a zero score in a young person. CTA adds anatomic detail beyond calcium scoring and can help refine risk, but its value depends heavily on the patient and clinician using it. Growth hormone signaling is deeply tied to liver gene expression, IGF-1 production, fat metabolism, and insulin sensitivity, making it relevant to aging and cardiometabolic disease. Exogenous growth hormone is unlikely to improve longevity and may worsen cardiometabolic risk, though it may improve body composition or subjective well-being in some people. Real-time biomarker feedback, such as acetone breath testing, may help people change behavior more effectively than weight scales alone.
Data Points: Podcast funding model: 0 ads - The Drive is funded entirely by listener support rather than advertising. Member benefits: Full access to exclusive show notes and downloadable transcripts - Described as part of the subscription model for supporters. Member access: AMA episodes included - Members can ask questions through the AMA portal and listen to those episodes. MI causation: ~99% - Weiss states that about 99% of heart attacks in the U.S. are due to ruptured atherosclerotic plaque. Historical plaque ruptures: Average of 7 - Davies’ autopsy series reportedly found about seven plaque ruptures in the culprit artery before death. STEMI treatment target: Within 1 hour - Current standard is cath lab activation and artery opening rapidly after STEMI presentation. Coronary stenosis threshold for symptoms: ~70% diameter stenosis - Often the point at which stable angina becomes clinically apparent and stress tests become positive. CT angiogram radiation: ~2 millisieverts - Modern top-tier CT angiography scanners can deliver relatively low radiation exposure. Annual radiation reference: 50 millisieverts - Cited as an upper limit/suggested annual exposure benchmark. Sea-level background radiation: ~1 millisievert/year - Used to contextualize CT angiography radiation exposure. Denver background radiation: ~4-5 millisieverts/year - Used as another comparison point for CT radiation exposure. CTA cost: ~$2,000-$2,500 - Attia and Weiss discuss the relatively high out-of-pocket cost of CT angiography in some settings. Calcium score example: 1,300 - A 50-something asymptomatic patient with very high coronary calcium used as an example of high-risk primary prevention. Calcium score example: 4,500 - A 49-year-old patient cited as an extreme calcium score case. Laron syndrome cohort: ~300 patients - Weiss references the Ecuadorian cohort often discussed in IGF/GH longevity literature. Mouse lifespan record: 1,819 days - A GHR-knockout mouse engineered by Bartke/Kopchick is described as the longest-lived mouse model. Fatty liver phenotype: 25-fold increase - Selective hepatic JAK2 deletion caused a dramatic increase in liver lipid accumulation. IGF-1 source: ~95% liver-derived - Weiss notes that most circulating IGF-1 comes from the liver. Fasting effect on IGF-1: Drops into the 80s-90s - During a 6-7 day water fast, his IGF-1 fell to very low levels. IGF-1 rebound: ~6 weeks - He reports it takes about six weeks for IGF-1 to return to baseline after fasting. Growth hormone trial year: 1983 - He cites a New England Journal study showing growth hormone increased insulin needs in type 1 diabetes. Stent antiplatelet duration: 1 month for bare-metal stents; ~6 months for many drug-eluting stents - He describes historical and current dual antiplatelet therapy durations.
Pivotal Quotes: "I don't know how you could trust me if I'm telling you about something when you know I'm being paid by the company that makes it to tell you about it." — Peter Attia: Explaining why the podcast avoids ads and relies on listener support. "What kills you is the acute thing." — Ethan Weiss: Summarizing the difference between chronic stable coronary disease and acute plaque rupture events. "If you show up in the hospital with this ST elevation MI, a STEMI... it's do not pass, do not collect $200. You're going straight to the cath." — Ethan Weiss: Describing the urgency and standard treatment pathway for STEMI.
Implications: Listeners should understand that stents are lifesaving in STEMI but mainly symptom tools in stable disease, and that risk assessment is still imperfect. The episode also suggests growth hormone/IGF biology may matter for aging, metabolism, and future therapies, while behavior feedback tools like Keyto may improve adherence.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.